Biogen Inc (BIIB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biogen Inc (BIIB) has a cash flow conversion efficiency ratio of 0.024x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($448.90 Million) by net assets ($18.85 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Biogen Inc for the company's overall valuation and market capitalisation.
Biogen Inc - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how Biogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biogen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biogen Inc ranked by their cash flow conversion efficiency. Explore Biogen Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jabil Circuit Inc
NYSE:JBL
|
0.403x |
|
Grupo Financiero Banorte S.A.B. de C.V
MX:GFNORTEO
|
-0.031x |
|
Eternal Limited
NSE:ETERNAL
|
-0.003x |
|
ANGLO AMERICAN SP.ADR 1/2
F:NGLD
|
N/A |
|
Roblox Corp
NYSE:RBLX
|
1.400x |
|
Banco Bradesco S.A
F:BREC
|
-0.288x |
|
HANN.RUECKV.SE ADR 1/2/ON
F:HNRB
|
0.128x |
|
ADYEN NV UNSP.ADR/001
F:1N8U
|
N/A |
Annual Cash Flow Conversion Efficiency for Biogen Inc (1989–2025)
The table below shows the annual cash flow conversion efficiency of Biogen Inc from 1989 to 2025. View Biogen Inc (BIIB) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.26 Billion | $2.20 Billion | 0.121x | -29.80% |
| 2024-12-31 | $16.72 Billion | $2.88 Billion | 0.172x | +64.54% |
| 2023-12-31 | $14.80 Billion | $1.55 Billion | 0.105x | +1.11% |
| 2022-12-31 | $13.39 Billion | $1.38 Billion | 0.103x | -68.87% |
| 2021-12-31 | $10.96 Billion | $3.64 Billion | 0.332x | -16.09% |
| 2020-12-31 | $10.69 Billion | $4.23 Billion | 0.396x | -25.41% |
| 2019-12-31 | $13.34 Billion | $7.08 Billion | 0.531x | +11.76% |
| 2018-12-31 | $13.03 Billion | $6.19 Billion | 0.475x | +31.44% |
| 2017-12-31 | $12.60 Billion | $4.55 Billion | 0.361x | -3.12% |
| 2016-12-31 | $12.13 Billion | $4.52 Billion | 0.373x | -5.93% |
| 2015-12-31 | $9.37 Billion | $3.72 Billion | 0.396x | +45.70% |
| 2014-12-31 | $10.81 Billion | $2.94 Billion | 0.272x | +0.01% |
| 2013-12-31 | $8.62 Billion | $2.35 Billion | 0.272x | +0.77% |
| 2012-12-31 | $6.96 Billion | $1.88 Billion | 0.270x | +0.42% |
| 2011-12-31 | $6.43 Billion | $1.73 Billion | 0.269x | -9.83% |
| 2010-12-31 | $5.45 Billion | $1.62 Billion | 0.298x | +73.68% |
| 2009-12-31 | $6.26 Billion | $1.07 Billion | 0.172x | -36.30% |
| 2008-12-31 | $5.81 Billion | $1.56 Billion | 0.269x | +46.11% |
| 2007-12-31 | $5.53 Billion | $1.02 Billion | 0.184x | +56.74% |
| 2006-12-31 | $7.15 Billion | $841.27 Million | 0.118x | -8.65% |
| 2005-12-31 | $6.91 Billion | $889.50 Million | 0.129x | +20.78% |
| 2004-12-31 | $6.83 Billion | $727.99 Million | 0.107x | +243.13% |
| 2003-12-31 | $7.05 Billion | $219.21 Million | 0.031x | -81.43% |
| 2002-12-31 | $1.60 Billion | $267.08 Million | 0.167x | -28.63% |
| 2001-12-31 | $1.35 Billion | $316.36 Million | 0.235x | -29.09% |
| 2000-12-31 | $1.11 Billion | $365.94 Million | 0.331x | +18.98% |
| 1999-12-31 | $979.53 Million | $272.29 Million | 0.278x | +19.01% |
| 1998-12-31 | $718.61 Million | $167.84 Million | 0.234x | +28.30% |
| 1997-12-31 | $536.29 Million | $97.63 Million | 0.182x | +89.47% |
| 1996-12-31 | $484.37 Million | $46.54 Million | 0.096x | +289.43% |
| 1995-12-31 | $382.98 Million | $9.45 Million | 0.025x | -76.67% |
| 1994-12-31 | $329.93 Million | $34.89 Million | 0.106x | -27.76% |
| 1993-12-31 | $325.20 Million | $47.60 Million | 0.146x | -3.21% |
| 1992-12-31 | $285.00 Million | $43.10 Million | 0.151x | +512.60% |
| 1991-12-31 | $239.00 Million | $5.90 Million | 0.025x | -66.39% |
| 1990-12-31 | $145.70 Million | $10.70 Million | 0.073x | +236.30% |
| 1989-12-31 | $139.20 Million | $-7.50 Million | -0.054x | -- |
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psorias… Read more